Antiphospholipid syndrome is characterized by thrombosis and positive antibodies measured on 2 occasions 12 weeks apart, increasing the risk of cardiovascular events.
Patients with Antiphospholipid Syndrome (APS)
Improved understanding of the pathogenic function of antiphospholipid antibodies could help in risk stratification and provide new molecular therapeutic targets for APS.
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by venous thromboembolism, arterial thrombosis, and obstetric morbidities in the setting of persistently positive levels of antiphospholipid antibodies measured on 2 different occasions 12 weeks apart. Patients with APS are at increased risk for accelerated atherosclerosis, myocardial infarction, stroke, and valvular heart disease. Vascular endothelial cell dysfunction mediated by antiphospholipid antibodies and subsequent complement system activation play a cardinal role in APS pathogenesis. Improved understanding of their pathogenic function could help in the risk stratification of patients with APS and provide new molecular therapeutic targets.
Building similarity graph...
Analyzing shared references across papers
Michel Corban
Alí Duarte‐García
Robert D. McBane
Journal of the American College of Cardiology
Mayo Clinic
Mayo Clinic in Arizona
Mayo Clinic in Florida
Building similarity graph...
Analyzing shared references across papers
Corban et al. (Mon,) conducted a review in Antiphospholipid syndrome. Antiphospholipid syndrome is characterized by thrombosis and positive antibodies measured on 2 occasions 12 weeks apart, increasing the risk of cardiovascular events.
www.synapsesocial.com/papers/69eb3584bd73c2fec3bb0c25 — DOI: https://doi.org/10.1016/j.jacc.2017.02.058
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: